Abstract:BackgroundBeckman Coulter developed a fully automated Access HIV Ag/Ab combo assay for the new DxI 9000 Access Immunoassay analyzer that reports separate results for HIV-1 p24 antigen (Ag) and HIV-1/2 antibody (Ab) with a 30 minute time to first result and a sample volume of only 60 μL. Evaluation of the Access HIV Ag/Ab combo assay assessed analytical sensitivity for seroconversion panels, HIV-1 p24 Ag (WHO I.S. NIBSC code 90/636), and HIV-1 and HIV-2 Ag from different viral strains. Clinical specificity and sensitivity of this 4 th generation assay was also assessed.MethodsThirty commercially available seroconversion panels were assessed on Access HIV Ag/Ab combo (3 lots), Abbott Architect HIV Ag/Ab Combo, and Roche Elecsys HIV Duo assays. The HIV-1 p24 Ag analytical sensitivity of the Access assay was performed on dilutions of HIV-1 p24 Ag WHO I.S. prepared in HIV negative human serum and plasma, ranging from 0.1 to 1.0 IU/mL. Fifty positive viral lysates from HIV-1 group M (A-H subtypes, CRF01, CRF02, CRF06, CRF11, CRF14, CRF15, CRF18, CRF36), HIV-1 group O (H and T subgroups), and HIV-2 (groups A and B) were spiked into HIV negative human CPD plasma and tested on both the Access and Architect assays. Clinical sensitivity and specificity were determined for the Access assay using the Architect assay as comparator by testing samples from HIV low risk, high risk and HIV known positive populations at three US clinical laboratories. An HIV 1/2 differentiation assay and HIV-1 RNA PCR were also run to confirm patient infection status.ResultsThe Access HIV Ag/Ab combo assay detected a higher number of bleeds (n=90) than the Elecsys (n = 80) and Architect (n = 77) assays due to earlier Ag detection. The average number of days between positive detection of a bleed previously identified Nucleic Acid Test (NAT) positive compared to these assays was reduced by 1.2 to 1.6 days (Access = 6.8 days; Elecsys = 8.0 days; Architect = 8.4 days). The Access assay also offered a limit of detection for the HIV-1 p24 Ag WHO I.S. between 0.19 and 0.22 IU/mL and a higher sensitivity for HIV-1 p24 Ag compared to the Architect assay: overall median Signal/Cut-Off (S/CO) for the 46 HIV-1 strains = 2.45 with the Access assay when the Architect assay S/CO was normalized at 1.00. HIV-2 strains were not included in this calculation since they were not detected by the Architect assay. A clinical validation study demonstrated 100.0% sensitivity for Access (n= 1,787; 95% CI: 99.8-100.0%) vs 99.8% for the Architect assay (n=1,786; 95% CI: 99.5-99.9%) and 99.7% specificity for Access (n=8,467; 95% CI: 99.5-99.8%) vs 98.8% for the Architect assay (n= 8,467, 95% CI: 98.6-99.0).ConclusionsThe new Access HIV Ag/Ab combo assay demonstrated excellent analytical performances, particularly its high HIV-1 p24 Ag sensitivity, which could help reduce the diagnosis window and thus prevent any delay of treatment for an infected patient. Furthermore, the Access assay showed clinical sensitivity and specificity performance meeting or exceeding that of currently marketed HIV combo immunoassays.

Evaluation of the ELITechGroup solution for plasma HIV-1 RNA quantification

Evaluation of the analytical and clinical performance of the Abbott Alinity m instrument for the quantification of HIV-1 RNA plasma viral load in a reference laboratory in Rio de Janeiro, Brazil

Application of a commercial kit for detection of PCR products to quantification of human immunodeficiency virus type 1 RNA and proviral DNA

Performance evaluation of the quantitative assay Adenovirus ELITe MGB® Kit on EDTA-plasma, using the ELITe BeGenius® system

Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories

High sensitivity detection of HIV-1 using two genomic targets compared with single target PCR

Clinical evaluation of patterned dried plasma spot cards to support quantification of HIV viral load and reflexive genotyping

Human immunodeficiency virus type 1 (HIV-1) proviral DNA load in purified CD4+ cells by LightCycler® Real-time PCR

Replicate Aptima Assay for Quantifying Residual Plasma Viremia in Individuals on Antiretroviral Therapy

Quantification of the HIV-integrase inhibitor raltegravir and detection of its main metabolite in human plasma, dried blood spots and peripheral blood mononuclear cell lysate by means of high-performance liquid chromatography tandem mass spectrometry

Evaluation of Performance Characteristics of the Aptima CMV Quant Assay for the Detection and Quantitation of CMV DNA in Plasma Samples

Performance evaluation of the high-throughput quantitative Alinity m Epstein-Barr virus assay

Evaluation of the Alinity m CMV assay for detecting and quantifying cytomegalovirus DNA in non-plasma samples

Sensitivity and specificity of the new Bio-Rad HIV screening test, Access HIV combo V2

A real time PCR platform for the simultaneous quantification of total and extrachromosomal HIV DNA forms in blood of HIV-1 infected patients

B-058 Multicenter Evaluation of the new Access HIV Ag/Ab combo Assay With Highly Sensitive HIV-1 p24 Antigen Detection on the DxI 9000 Access Immunoassay Analyzer

The MTB/MDR ELITe MGB® Kit: Performance Assessment for Pulmonary, Extra-Pulmonary, and Resistant Tuberculosis Diagnosis, and Integration in the Laboratory Workflow of a French Center

Performance Evaluation of the New Chemiluminescence Immunoassay CL-1200i for HBV, HIV Panels

From Capillary Electrophoresis to Deep Sequencing: An Improved HIV-1 Drug Resistance Assessment Solution Using In Vitro Diagnostic (IVD) Assays and Software

Evaluation of two automated real-time PCR-based quantification methods for whole blood Epstein-Barr viral load

Evaluation of the Aptima HBV Quant Assay Compared to Abbott RealTime M2000 HBV Quant Assay and Procleix Ultrio Plus dHBV Assay in Plasma Samples